Cancers treated with radiotherapy
Conditions
Interventions
None listed
Sponsors
National Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria 1) to 5) 1) Cancer patients who received radiotherapy at the collaborating institutions between January 2012 and March 2022. 2) Patients who showed an exceptional response to radiotherapy that deviated from the expected radiation dose-effect relationship. 3) Patients who did not receive any drugs to reduce the size of the cancer during radiotherapy. 4) Patients who are 20 years of age or older at the time of radiotherapy. 5) Patients with one or more of the following existing samples available for genetic analysis or histopathological evaluation: A) Excess tumor tissue samples collected for diagnosis. B) Surplus tumor tissue samples obtained at surgery. C) Excess tumor tissue samples stored in the biobank of each institution, for which consent for the use of biobank samples has been obtained from the patient.
Exclusion criteria
Exclusion criteria: 1) Patients with a history of prior radiotherapy for lesions exhibiting exceptional response. 2) Patients unsuitable for the study judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of genetic alterations in tumor tissues such as somatic mutations, copy number alterations, aberrant expression, and structural variants | — |
Secondary
| Measure | Time frame |
|---|---|
| Altered gene pathways, tumor immune response, germline mutations, overall survival, progression-free survival, local progression-free survival, duration of response | — |
Countries
Japan
Contacts
Public ContactHidenari Hirata
National Cancer Center Hospital East, Department of Radiation Oncology
Outcome results
None listed